Leerink sets $36 price target for Latigo Biotherapeutics
Latigo Biotherapeutics was initiated at an Outperform rating by Leerink Partners, with a $36.00/share price target announced, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.